deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT03827395

Safety Study of Hepatitis E Vaccine (HEV239)

A Phase 1, Double-Blinded, Placebo Controlled, Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of HEV-239 (Hecolin(R)) in a Healthy US Adult Population

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Hepatitis E Immunisation
Interventions HEV 239 Placebo
Updated 18 times since 2019 Last updated: Sep 23, 2021 Started: Apr 12, 2019 Primary completion: Aug 28, 2020 Completion: Aug 28, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hepatitis E and Immunisation, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 18 data snapshots since 2019. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jan 2020 · 7 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Oct 2021 · 4 months · monthly snapshot~Oct 2021 – ~Jul 2024 · 33 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Oct 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2021 — Oct 2021 [monthly]

    Completed PHASE1

  5. Jan 2021 — Jun 2021 [monthly]

    Completed PHASE1

▶ Show 13 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE1

  2. Oct 2020 — Nov 2020 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  3. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

  4. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Jun 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

  6. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE1

  7. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE1

  8. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE1

  9. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE1

  10. Jun 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  11. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  12. Apr 2019 — May 2019 [monthly]

    Not Yet Recruiting PHASE1

  13. Mar 2019 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations